UCB PREVIEW: Upcoming phase 3 data from Bimzelx competitor in HS
Upcoming phase 3 data from Bimzelx competitor, sonelokimab (IL17A/F nanobody), in HS is expected in September. In this note, we preview the readout and outline a few potential scenarios, highlighting the potential upside/downside for UCB's stock. While the stock may take a hit if sonelokimab shows a numerical difference on the primary endpoint, this will depend on the extent of the delta, and we see more limited downside if the numerical difference is on the smaller end, particularly in the context of cross- trial differences. We believe UCB is well positioned with Bimzelx given its broad labe...